'The US_FDA never had the authority or the science to approve chemical abortion drugs, and it is time for a court to order the FDA to put politics aside, follow the science, and protect women and girls,' Julie Marie Blake writes.
who have come to the emergency room after taking chemical abortion drugs with gruesome complications, including passing blood clots the size of lemons, severe cramping and pain, and serious infections caused by parts of the baby being left in the womb. Some women bleed for several weeks after taking chemical abortion drugs. Others must undergo an emergency surgical abortion.
Yet the FDA insists that chemical abortions require fewer and fewer safeguards. The agency decided it did not need further studies or additional information about nonfatal adverse events from abortionists in America, and it claims that no data exist to show that the chemical abortion drugs are not safe. That position runs counter to all the evidence before doctors’ eyes. And it runs counter to the FDA’s responsibility to ensure, beforehand, the safety of the drugs it approves.
But these conditions are not required for women seeking chemical abortion drugs. Today, if a woman receives an abortion pill, she never has to see a doctor, no one needs to conduct any tests to confirm how far along she is, and no one needs to follow up in person to ensure she’s OK. She can receive the drugs through the mail, take them alone and unsupervised, and end up in a dangerous situation — all without any input from a doctor.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
How a Texas judge is poised to ban the abortion pillJudge Matthew Kacsmaryk will rule on the FDA’s approval of mifepristone
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalThe medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021.
Weiterlesen »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Weiterlesen »
Paxlovid not linked to COVID rebound, FDA saysThe FDA gave the COVID-19 anti-viral emergency use authorization in 2021 for treating mild to moderate illness in high-risk adults.
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalPfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers, clearing the way for its full approval by the FDA. The medication has been used by millions of Americans since it was granted emergency use authorization in 2021.
Weiterlesen »